An Open Label, Non-Randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure.

Trial Profile

An Open Label, Non-Randomised Study to Explore Safety/Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 in Patients With Stable Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2015

At a glance

  • Drugs Sacubitril/valsartan (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Biomarker; Pharmacodynamics
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 24 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 09 Dec 2009 Planned end date (July 2009) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top